Comparative Pharmacology
Head-to-head clinical analysis: FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE versus RENESE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE versus RENESE.
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE vs RENESE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fosinopril is an ACE inhibitor that inhibits the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
Thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing sodium and chloride reabsorption, leading to increased diuresis and vasodilation.
1 tablet (fosinopril 10 mg/hydrochlorothiazide 12.5 mg or fosinopril 20 mg/hydrochlorothiazide 12.5 mg) orally once daily. Maximum dose: fosinopril 80 mg/hydrochlorothiazide 50 mg per day.
Initial 2.5-5 mg orally once daily; increase by 2.5-5 mg every 2-4 weeks up to 20 mg/day as needed.
None Documented
None Documented
Fosinoprilat: 11.5 h (terminal); Hydrochlorothiazide: 6-15 h (biphasic, terminal phase 10-15 h).
13–15 hours; prolonged in renal impairment (CrCl <30 mL/min: up to 30–40 hours).
Fosinopril: 45% renal, 55% biliary/fecal; Hydrochlorothiazide: >95% renal (unchanged).
Renal: ~85% unchanged; fecal: ~15% (via bile).
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic